Confluent Surgical, Inc
% Mr. James McMahon
Senior Associate, Regulatory Affairs
101A First Avenue
Waltham, Massachusetts 02451

Re: P080013
DuraSeal Xact™ Sealant System
Filed: April 25, 2008
Amended: June 27, October 21, 2008 and July 22, 2009
Procode: NQR

Dear Mr. McMahon:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the DuraSeal Xact™ Sealant System. This device is indicated for use as an adjunct to sutured dural repair during spinal surgery to provide watertight closure. The PMA supplement is approved. You may begin commercial distribution of the device in accordance with the conditions described below.

The sale and distribution of this device are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). FDA has determined that this restriction on sale and distribution is necessary to provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Expiration dating for this device has been established and approved at 18 months at 25°C. This is to advise you that the real-time aging protocol you used to establish this expiration dating is considered an approved protocol for the purpose of extending the expiration dating as provided by 21 CFR 814.39(a)(7).

Continued approval of this PMA is contingent upon the submission of periodic post-approval reports required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. Two copies of this report, identified as "Annual Report" and bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.
In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

In addition to the Annual Report requirements, you have agreed to provide the following data in post-approval study reports (PAS), as described in items below and the post-approval study outline you sent to the Division of Epidemiology via email on July 17, 2009. Two copies, identified as "PMA Post-Approval Report" and bearing the applicable PMA reference number, should be submitted to the address below.

The post-approval study is a multi-center, non-randomized study with a prospective DuraSeal treatment arm and a retrospective standard of care control arm, designed to estimate the rates of post-operative CSF leak, deep surgical site infection (SSI), and neurological Serious Adverse Events (SAEs) at 90 days for the DuraSeal Spinal Sealant arm and compare these rates to the corresponding rates for the control arm. The DuraSeal Spinal Sealant Prospective Treatment arm will enroll 305 subjects from up to 40 sites within the United States. Subjects undergoing spinal surgery where there is a possibility of opening of the dura (either intentional or incidental) will be consented prior to surgery. The Retrospective Standard of Care Control arm will enroll 683 subjects identified in a retrospective review of medical charts at the same study centers for a pre-defined time period (1 year) as patients who have undergone a spinal procedure and received treatment for an opening of the dura (either intentional or incidental). All cases that meet eligibility criteria within the pre-specified time period will be included. For both arms, you have agreed to collect information about patient demographics, medical history and documented procedural data (such as indication for surgery, procedure(s) performed, level(s) of surgery, surgical approach, dural opening details, other control products, etc.). You also agreed to collect information documenting the incidence of CSF Leak, deep SSI, and all neurosurgical SAEs at 90-days post-operation. The primary hypothesis to be tested in this study is the non-inferiority of DuraSeal Spinal Sealant to control treatment with respect to CSF leakage at 90-day post-procedure using a non-inferiority margin of 5% after accounting for the potential imbalance between the two groups on confounders of the relationship between treatment for a dural opening and CSF leakage.

Every six months for the first two years and then annually until the study is completed you are to submit a progress report to the FDA that includes, but is not limited to, the status of site enrollment, the status of patient enrollment, the status of patient follow-up, and other milestones as they compare to the stated goals in the protocol and an explanation for a delay, if any in meeting these goals, and the safety and effectiveness data collected during that reporting period.
You must also update your patient and physician labeling (via a PMA supplement) to reflect the findings in the PAS, as soon as these data are available, as well as any other time-point deemed necessary by FDA if significant new information from this study becomes available.

For additional information about the development of the post-approval study protocol, please contact the Office of Surveillance and Biometrics, Division of Epidemiology, Dr. Cunlin Wang, telephone 301-796-6071.

Be advised that the failure to conduct any such study in compliance with the good clinical laboratory practices in 21 CFR part 58 (if a non-clinical study subject to part 58) or the institutional review board regulations in 21 CFR part 56 and the informed consent regulations in 21 CFR part 50 (if a clinical study involving human subjects) may be grounds for FDA withdrawal of approval of the PMA.

Within 30 days of your receipt of this letter, you must submit a PMA supplement that includes a complete protocol of your post-approval study. Your PMA supplement should be clearly labeled as a "Post-Approval Study Protocol" and submitted in triplicate to the address below. Please reference the PMA number above to facilitate processing. If there are multiple protocols being finalized after PMA approval, please submit each protocol as a separate PMA supplement. For more information on post-approval studies, see the FDA guidance document entitled, "Procedures for Handling Post-Approval Studies Imposed by PMA Order" (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070974.htm#2).

Before making any change affecting the safety or effectiveness of the device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm).

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

In accordance with the recall requirements specified in 21 CFR 806.10, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at www.fda.gov/Safety/Recalls/IndustryGuidance/default.htm.

CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet Home Page located at www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm. Written requests for this information can also be made to the Dockets Management Branch, (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with copies of all approved labeling in final printed form. Final printed labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final printed labeling is identical to the labeling approved in draft form. If the final printed labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.
All required documents should be submitted in triplicate, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing. One of those three copies may be an electronic copy (eCopy), in an electronic format that FDA can process, review and archive (general information: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm134508.htm; clinical and statistical data: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm136377.htm)

U.S. Food and Drug Administration
Center for Devices and Radiological Health
PMA Document Mail Center – WO66-G609
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

If you have any questions concerning this approval order, please contact George K Ngatha at 301-796-6970.

Sincerely yours,

Mark N. Mckerson
Director
Division of Surgical, Orthopedic, and Restorative Devices
Office of Device Evaluation
Center for Devices and Radiological Health